![]() Niznik was initially reluctant to sell his holdings and forced Synergy to up its bid to the final £8 agreed after an initial offer of £7 at the end of October. The stake was built later than Niznik’s but was being taken as early as 2003 so should have captured much of the upside. (THRA) The open-ended fund holds 1.5 million shares, amounting to 6.97% of the fund. As a medical equipment and solutions supplier with a deep focus on healthcare, Mindray strives to develop and share medical technologies and devotes to. The other main beneficiary is AXA Framlington, which had a stake of around 18% before the Synergy offer, mainly held through George Luckraft’s equity income fund and Throgmorton investment trust. Niznik will sell off his entire holding of 610,000 shares, some 2.8% to Synergy. Synergy Healthcare is a leading clinical research center. ![]() He bought at around £3, so has more than doubled his money.Īcross Standard Life’s funds the firm had a stake of around 13%. Helping Build a Positive Healthcare Ecosystem. The stock was one of the holdings Citywire AAA-rated Mark Niznik launched the Standard Life UK Opportunities fund (Standard Life UK Opportunities-Life) with in 2002. This week Synergy secured acceptance from more than 90% of shareholders for its recommended bid for sterilisation plant provider Isotron. AXA Framlington and Standard Life Investment funds are the main beneficiaries of Synergy Healthcare’s buy-out of Isotron. The company offers hospital sterilization services for the reusable medical and surgical equipment used in operating theatres.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |